博瑞医药(688166.SH)：BGM0504注射液减重适应症Ⅲ期临床试验达成预期目标

智通财经05-05

智通财经APP讯，博瑞医药(688166.SH)公告，近日，公司全资子公司博瑞制药(苏州)有限公司自主研发的BGM0504注射液减重适应症Ⅲ期临床试验达成预期目标。据悉，BGM0504-Ⅲ-WL是一项在中国41家临床中心开展的评估BGM0504注射液用于中国非糖尿病的超重或肥胖成人体重管理的临床有效性和安全性的Ⅲ期临床研究(登记号：CTR20243983/NCT06704581)，获得积极顶线结果...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2633990355?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-05 15:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633990355","market":"hk","top_or_hot":-1,"title":"博瑞医药(688166.SH)：BGM0504注射液减重适应症Ⅲ期临床试验达成预期目标","media":"智通财经","content":"<div>\n<p>智通财经APP讯，博瑞医药(688166.SH)公告，近日，公司全资子公司博瑞制药(苏州)有限公司自主研发的BGM0504注射液减重适应症Ⅲ期临床试验达成预期目标。据悉，BGM0504-Ⅲ-WL是一项在中国41家临床中心开展的评估BGM0504注射液用于中国非糖尿病的超重或肥胖成人体重管理的临床有效性和安全性的Ⅲ期临床研究(登记号：CTR20243983/NCT06704581)，获得积极顶线结果...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1438064.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>博瑞医药(688166.SH)：BGM0504注射液减重适应症Ⅲ期临床试验达成预期目标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n博瑞医药(688166.SH)：BGM0504注射液减重适应症Ⅲ期临床试验达成预期目标\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-05 15:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1438064.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，博瑞医药(688166.SH)公告，近日，公司全资子公司博瑞制药(苏州)有限公司自主研发的BGM0504注射液减重适应症Ⅲ期临床试验达成预期目标。据悉，BGM0504-Ⅲ-WL是一项在中国41家临床中心开展的评估BGM0504注射液用于中国非糖尿病的超重或肥胖成人体重管理的临床有效性和安全性的Ⅲ期临床研究(登记号：CTR20243983/NCT06704581)，获得积极顶线结果...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1438064.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1438064.html","article_id":"2633990355","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633990355","pubTimestamp":1777967316,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，博瑞医药 公告，近日，公司全资子公司博瑞制药(苏州)有限公司自主研发的BGM0504注射液减重适应症Ⅲ期临床试验达成预期目标。本研究共入组652例超重或肥胖参与者，所有入组参与者的平均基线体重为96.2kg，平均基线BMI为33.9kg/m2，各剂量组间基线特征整体均衡。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688166":"博瑞医药","BK0239":"医药制造"},"translate_title":"Borui Pharmaceuticals (688166.SH): Phase III clinical trial of BGM0504 injection for weight loss indication achieves expected goal","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688166":1.5},"content_text":"智通财经APP讯，博瑞医药(688166.SH)公告，近日，公司全资子公司博瑞制药(苏州)有限公司自主研发的BGM0504注射液减重适应症Ⅲ期临床试验达成预期目标。据悉，BGM0504-Ⅲ-WL是一项在中国41家临床中心开展的评估BGM0504注射液用于中国非糖尿病的超重或肥胖成人体重管理的临床有效性和安全性的Ⅲ期临床研究(登记号：CTR20243983/NCT06704581)，获得积极顶线结果，达成主要终点及所有关键次要终点。本研究共入组652例超重或肥胖参与者(包括了部分基线合并有高血压以及基线血压未达标的参与者，且这些参与者整个研究期间基本未使用其他降压药物)，所有入组参与者的平均基线体重为96.2kg，平均基线BMI为33.9kg/m2，各剂量组间基线特征整体均衡。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633990355","isCrawlerRequest":true}